Envafolimab(KN035)* is an independently developed subcutaneous PD-L1 single-domain antibody Fc fusion protein. It was approved for marketing in China in November 2021, for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors.

Envafolimab efficiently blocks the binding of PD-1 and PD-L1, thereby activating an immune response against tumors. With a molecular weight half that of a conventional antibody, it exhibits enhanced tissue penetration and reaches tumor tissues via the lymphatic circulation system.

Envafolimab has been granted two Orphan Drug Designations by the U.S. Food and Drug Administration (FDA) for the treatment of advanced biliary tract cancer and soft tissue sarcoma; it has been granted Breakthrough Therapy Designation by the National Medical Products Administration (NMPA) for the treatment of unresectable or metastatic solid tumors with high tumor mutation burden (TMB-H).

Anbenitamab (KN026)* is an anti-HER2 bispecific antibody developed using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). Anbenitamab can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade. Through antibody-induced receptor clustering, it enhances ADCC and CDC effects while promoting the down-regulation of HER2 receptors on the cell surface.

In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the National Medical Products Administration (NMPA) for the treatment of HER2-positive gastric cancer (GC). Currently, several pivotal clinical trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive breast cancer (BC), neoadjuvant treatment of HER2-positive BC are being conducted.

Anbenitamab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive or low expressing GC; it has been granted Breakthrough Therapy Designation by NMPA for the treatment of patients with HER2-positive GC/GEJ who have failed first-line standard treatment.

JSKN003 is an anti-HER2 biparatopic antibody-drug conjugate (ADC), which is developed inhouse with Alphamab’s proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme catalytic reaction and click chemistry to achieve a drug-to-antibody ratio (DAR) of approximately 4. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects.

Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. JSKN003 shows good safety profile and efficacy in preclinical studies in both high and low HER2- expression models (CDX+PDX).

JSKN016 is a bispecific antibody conjugated drug (ADC) targeting HER3 (Human epidermal growth factor receptor 3) and TROP2 (Trophoblast cell surface antigen 2), which is developed inhouse with proprietary Glycan-specific conjugation platform.

After binding with TROP2 and/or HER3 on the surface of tumor cells, JSKN016 enters the lysosome through target-mediated endocytosis, releasing cytotoxic topoisomerase I inhibitor (TOPIi), and then inducing apoptosis of TROP2 and/or HER3 positive tumor cells. In addition, the inhibitor can penetrate the cell membrane and enter the antigen-negative tumor cells to exert bystander effect. These effects can effectively inhibit the growth of tumor cells.

JSKN022 is a first-in-class antibody-drug conjugate (ADC) targeting both PD-L1 and integrin αvβ6. It is produced through enzymatic catalysis of glycans followed by a click chemistry reaction, resulting in a site-specific conjugate with a drug-to-antibody ratio (DAR) of approximately 4.

KN019 is a biosimilar of Belatacept (Nulojix®).

KN019 has completed Phase II clinical study with positive results. In November 2023, KN019 received clinical trial approval from the National Medical Products Administration (NMPA) for its subcutaneous formulation.

KN046 is an independently developed PD-L1/CTLA-4 bispecific antibody, engineered to target the tumor microenvironment with high PD-L1 expression, and Treg (suppress tumor immunity) clearing function.

Multiple clinical trials of KN046 are ongoing in China, the U.S., and Australia.